Document is current
Any future updates will be listed below
-
Authors
Lokki, A. Inkeri https://orcid.org/0000-0003-4397-8415
Triebwasser, Michael
Daly, Emma
,
Heinonen, Seppo
Kajantie, Eero
Kere, Juha
Kivinen, Katja
Pouta, Anneli
Kurki, Mitja I.
Perola, Markus
Auro, Kirsi
Salmon, Jane E.
Anuja, Java
Daly, Mark
Atkinson, John P. https://orcid.org/0000-0002-2514-3441
Laivuori, Hannele https://orcid.org/0000-0003-3212-7826
Meri, Seppo
-
Funding
Funding for this research was provided by:
Alfred Kordelinin Säätiö (na)
U.S. Department of Health & Human Services | National Institutes of Health (U54 HL112303, R01 GM099111)
Jane ja Aatos Erkon Säätiö (na)
Päivikki ja Sakari Sohlbergin Säätiö (na)
Suomen Akatemia | Terveyden Tutkimuksen Toimikunta (121196, 278941)
Sigrid Juséliuksen Säätiö (na)
- License Information
-
More Information
Article History
Received: 18 March 2024
Revised: 11 October 2024
Accepted: 22 November 2024
First Online: 17 December 2024
Competing interests
: AJ serves on the scientific advisory boards of Alexion, AstraZeneca Rare Disease, and Novartis International AG, and serves as a consultant for Dianthus Therapeutics and Aurinia Pharmaceuticals. She has been a principal investigator for Apellis Pharmaceuticals and Novartis International AG. She also received royalty from UptoDate. HL received honoraria from Orion Corporation. JPA is part of the Scientific Advisory Board of Complement Corporation and Kypha, Inc., Scientific Advisory Board. Furthermore, he served as a consultant in Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc., Biothera and Clinical Pharmacy Services, CDMI. SM received honoraria from Alexion, AstraZeneca Rare Disease, Biogen, Merck, Pfizer, and UCB, and research funding from Alexion.
